---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-016224"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:21:46.838136+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inhibikase raises ~$10M via registered direct offering and private placement with warrants

## Summary
- Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.
- Issued unregistered warrants to purchase up to 11,627,908 shares at $0.75/share, exercisable for 5 years.
- Gross proceeds ~$10M; net proceeds for clinical trials, product development, and working capital.
- Terminated prior at-the-market equity distribution agreement with Piper Sandler (no sales made).
- H.C. Wainwright acted as exclusive placement agent; offering expected to close January 27, 2023.

## SEC filing metadata
- accession: 0001193125-23-016224
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/d369483d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-016224
- JSON: https://secwatch.observer/filing/0001193125-23-016224.json
- Plain text: https://secwatch.observer/filing/0001193125-23-016224.txt

## Key facts
- Material Agreements
  Inhibikase Therapeutics, Inc. entered into PIPE Purchase Agreement with the same institutional investor (effective 2023-01-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the same institutional investor
  - Effective: 2023-01-25
  source text: The Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) in connection with a concurrent private placement (the “PIPE Private Placement”) with the same institutional investor (the “PIPE Purchaser” and, together with the Registered Direct Purchaser, the “Purchaser”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm
- Material Agreements
  Inhibikase Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  source text: H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the Offerings. The Company entered into an engagement letter (“Engagement Letter”) with Wainwright for potential financings.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm
- Material Agreements
  Inhibikase Therapeutics, Inc. entered into Registered Direct Purchase Agreement with an institutional investor (effective 2023-01-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Effective: 2023-01-25
  source text: On January 25, 2023, Inhibikase Therapeutics, Inc. (“Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) in connection with a registered direct offering (the “Registered Direct Offering”) and concurrent private placement with an institutional investor (the “Registered Direct Purchaser”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.